Product Images Aminophylline

This is a description of Aminophylline Injection, USP with a concentration of 500mg in 20mL, to be used for intravenous use only. It contains aminophylline equivalent to 19.7mg/mL of anhydrous theophylline and may contain ethylenediamine for pH adjustment. This solution should not be used if crystals have separated from the solution, and the seal should be intact and undamaged to ensure sterility. The solution should be protected from light and promptly used with the unused portion discarded. There is no bacteriostat in this solution, and the usual dosage should be referred to from the insert. Distributed by Hospira, Inc. in Lake Forest, IL, USA.*

AMINOPHYLLINE INJ., USP 500mg/20mL (25mg/mL) is a sterile, nonpyrogenic drug used for IV use. It comes in a 20mL vial with the NDC code 51662-134171-2 and LOT number 12345. It is for RX only use and the usual dosage is to be seen through the insert. This medication should be protected from light and not used if the crystals have separated from the solution, or if the seal is damaged. Use aseptic technique and store it between 20 to 25°C (68 to 77°F). For more information, see the manufacturer's package insert. The original manufacturer's NDC code is 0409-5922-01.*

Aminophylline injection is a sterile, nonpyrogenic solution used for IV treatment. It contains 500mg/20mL (25mg/mL) and is stored at 20 to 25°C. The product is protected from light, and it's essential to check the solution's clarity and seal integrity before using it. The dosage information is available in the insert, and aseptic techniques should be followed during its usage. This product is manufactured by HF Acquisition Co., LLC, Mukilteo, WA 98275. Please see the manufacturer's package insert for more detailed information.*

This document appears to be a table showing the symptoms and occurrences of acute and chronic overdoses under various categories such as gastrointestinal, metabolic, cardiovascular, and neurological. It seems to show the percentage of patients exhibiting each symptom from the data collected.*

This is a table showing the Total Body Clearance, Half-Life, and Age Range for different population characteristics including: Premature neonates, Term infants, Children, Adults, Elderly, Concurrent Illness or Altered Physiological State, Liver Disease, Pregnancy, Sepsis, and Thyroid Disease. NR* indicates "not reported" and NRT indicates "not relevant to this age group or condition." The data can be used for clinical and pharmacological applications.*

This is a chart detailing the recommended maximum theophylline infusion rate in mg/kg/hr for different patient populations based on age and medical condition. The populations include neonates, young and older children, adolescents, adults, and elderly patients, some of which may be smokers or have specific medical conditions like cardiac decompensation, cor pulmonale, liver dysfunction, sepsis, or shock. The rates range from 0.31 to 1.5 mg/kg a12h/t depending on the patient population and condition.*

This text provides dosage adjustment recommendations based on the peak serum concentration of theophylline in patients. Different concentration ranges are provided with corresponding dosage adjustments, including increasing or decreasing the infusion rate and adding or stopping medication(s). The text emphasizes the importance of rechecking serum concentration and adjusting dosage accordingly. If meg/mL concentration is greater than 30, overdose treatment is required and subsequent infusion rate should be decreased by at least 50%.*

This is a product-listing description for a medication, with details regarding the unit of sale, total strength, total volume, concentration, National Drug Code (NDC) number, and packaging for two different product variations. The first variation has an NDC number of 0409-5921-01, contains 250mg of medicine per 10mL volume, and has 25 units packaged in a carton. The second variation has an NDC number of 0409-5922-01, contains 500mg of medicine per 20mL volume, and also has 25 units in a carton, with a concentration of 25mg/mL.*

This is a table of drug interactions related to theophylline concentration. It is a useful guide for healthcare professionals to understand how different drugs may affect the steady-state theophylline concentration in individual patients. The table indicates the type and effect of interaction for each drug and recommends precautions for patients taking theophylline with each of these drugs. The drugs causing interactions include alcohol, allopurinol, aminoglutethimide, carbamazepine, cimetidine, ciprofloxacin, clarithromycin, benzodiazepines, disulfiram, enoxacin, ephedrine, erythromycin, estrogen, fluvoxamine, halothane, interferon, isoproterenol, ketamine, lithium, lorazepam, methotrexate, mexiletine, midazolam, moricizine, pancuronium, pentoxifylline, phenobarbital, phenytoin, propafenone, propranolol, rifampin, sulfinpyrazone, tacrine, thiabendazole, ticlopidine, troleandomycin, and verapamil.*

This is a list of medications including albuterol, amoxicillin, atenolol, azithromycin, cefaclor, co-trimoxazole, diltiazem, dirithromycin, enflurane, famotidine, felodipine, finasteride, hydrocortisone, isoflurane, isoniazid, isradipine, influenza vaccine, ketoconazole, lomefloxacin, mebendazole, medroxyprogesterone, methylprednisolone, metronidazole, metoprolol, nadolol, nifedipine, nizatidine, norfloxacin, ofloxacin, omeprazole, prednisone, prednisolone, ranitidine, rifabutin, roxithromycin, sorbitol, sucralfate, terbutaline, terfenadine, tetracycline, tocainide.*

Description: This is a product label of a medicine named "AM I N 0 P HYLLI N E" which is a single-dose injection containing aminophylline and theophylline. The injection is sterile and nonpyrogenic, and each 20 mL dose contains 500 mg of aminophylline. The pH of the injection is 8.6 to 9.0, and it may contain ethylenediamine for pH adjustment. The label suggests not to use the injection if it is not clear or if the seal is damaged. The label also advises not to use the remains of the injection, rather discard them properly.*